SOLTI-1007 NeoEribulin (NCT01669252) is an open-label phase II pharmacogenomic study of single agent eribulin as neoadjuvant treatment for operable Stage I–II HER2-negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.